FindTrial
Sign In

Development of oral taurine therapy for the treatment of MERRF

Development of oral taurine therapy for the treatment of MERRF - Taurine therapy for MERRF

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009358
Enrollment
10
Registered
2012-11-19
Start date
2012-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MERRF

Interventions

Ten patients with MERRF having A8344G mutations in the mitochondrial DNA are enrolled in the study. Oral taurine (12g/d) is administered to the patients for 24 months to evaluate its effect on prevent

Sponsors

Department of Neurology, Kawasaki Medical School
Lead Sponsor
Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Nippon Medical School
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Male and female patients over 16 years old

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
-Frequency of seizure -Clinical score of cerebellar ataxia—

Countries

Japan

Contacts

Public ContactYutaka Ohsawa

Kawasaki Medical School Neurology

yosawa@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026